Krys Johnson-O'LEary

Krys Johnson-O'LEary

Auto-generated profile, based on publicly available information

Krys Johnson-O'LEary

America’s Poison Centers

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 December 2025 in Clinical Toxicology
Verified
Journal Article
Closed access
MBMichael C. Beuhler
Michael C. Beuhler
RFRyan Feldman
Ryan Feldman
DGDavid D. Gummin
David D. Gummin
JMJames B. Mowry
James B. Mowry
LRLaura J. Rivers
Laura J. Rivers
ABAlvin C. Bronstein
Alvin C. Bronstein
This is the 42nd Annual Report of America's Poison Centers® National Poison Data System®. As of 1 January, 2024, all 55 of the nation's Poison Centers uploaded case data automatically to NPDS. We analyzed the case data, tabulating specific indices from the NPDS. The methodology was as in previous years. Where changes were introduced, the differences are identified. Cases with medical outcomes of death were evaluated by a team of medical and clinical toxicologists using an ordinal scale of 1-6 to assess the Relative Contribution to Fatality of the exposure. In 2024, 2,418,426 closed encounters were logged by the National Poison Data System: 2,092,689 human exposures, 34,919 animal exposures, 285,736 information requests, 5,054 human confirmed nonexposures, and 28 animal confirmed nonexposures. The upload interval was 4.97 [4.32, 9.32] (median [25%, 75%]) minutes, creating a near real-time national exposure and information database and surveillance system. Total encounters remained essentially constant with a 0.117% decrease from 2023 while human exposure cases increased by 0.578% and health care facility human exposure cases increased by 0.661%. All information requests decreased by 2.70%, medication identification (Drug ID) requests decreased by 17.0%, and medical information requests showed a 24.5% decrease. Drug Information requests showed a 0.218% increase and comprised 22.4% of all information contacts. Human exposures with less serious outcomes have decreased by 1.45% per year since 2008, while those with more serious outcomes (moderate, major or death) have increased by 4.08% per year since 2000.Consistent with the previous year, the top 5 substance classes most frequently involved in all human exposures were analgesics (10.5%), household cleaning substances (6.94%), antidepressants (5.50%), cardiovascular drugs (5.12%) and cosmetics/personal care products (4.96%). As a class, stimulants and street drug exposures increased most rapidly, by 813 cases/year (4.54%/year) over the past 10 years for cases with more serious outcomes.The top 5 most common exposures in children aged 5 years or less were household cleaning substances (9.96%), cosmetics/personal care products (9.15%), analgesics (8.85%), foreign bodies/toys/miscellaneous (7.92%), and dietary supplements/herbals/homeopathic (6.34%).The National Poison Data System documented 2,809 human exposures resulting in death; 2,271 (80.9%) of these were judged as related (Relative Contribution to Fatality of 1-Undoubtedly responsible, 2-Probably responsible, or 3-Contributory). These data support the continued value of Poison Center expertise and the need for specialized medical toxicology information to manage the increasing number of more serious exposures. Unintentional and intentional exposures continue to be a significant cause of morbidity and mortality in the US. The near real-time nature of the National Poison Data System represents a national public health resource for collecting and monitoring US exposure cases and information requests. The continuing mission of the National Poison Data System is to provide a nationwide infrastructure for surveillance for all types of exposures (e.g., foreign body, infectious, venomous, chemical agent, or commercial product), and the identification and tracking of significant public health events. The National Poison Data System is a model system for the near real-time surveillance of national and global public health.

4 November 2021 in Epidemiology and Infection
Verified
Journal Article
Open access
PDF file
BIBénido Impouma
Bénido Impouma
FMFranck Mboussou
Franck Mboussou
BFBridget Lindsay Farham
Bridget Lindsay Farham
CWCaitlin M. Wolfe
Caitlin M. Wolfe
KJKrys Johnson
Krys Johnson
MMMatshidiso Moeti
Matshidiso Moeti
The World Health Organization African region recorded its first laboratory-confirmed coronavirus disease-2019 (COVID-19) cases on 25 February 2020. Two months later, all the 47 countries of the region were affected. The first anniversary of the pandemic occurred in a changed context with the emergence of new variants of concern (VOC) and growing COVID-19 fatigue. This study describes the epidemiological trajectory of COVID-19 in the region, summarises public health and social measures (PHSM) implemented and discusses their impact on the pandemic trajectory. As of 24 February 2021, the African region accounted for 2.5% of cases and 2.9% of deaths reported globally. Of the 13 countries that submitted detailed line listing of cases, the proportion of cases with at least one co-morbid condition was estimated at 3.3% of all cases. Hypertension, diabetes and human immunodeficiency virus (HIV) infection were the most common comorbid conditions, accounting for 11.1%, 7.1% and 5.0% of cases with comorbidities, respectively. Overall, the case fatality ratio (CFR) in patients with comorbid conditions was higher than in patients without comorbid conditions: 5.5% vs. 1.0% (P < 0.0001). Countries started to implement lockdown measures in early March 2020. This contributed to slow the spread of the pandemic at the early stage while the gradual ease of lockdowns from 20 April 2020 resulted in an upsurge. The second wave of the pandemic, which started in November 2020, coincided with the emergence of the new variants of concern. Only 0.08% of the population from six countries received at least one dose of the COVID-19 vaccine. It is critical to not only learn from the past 12 months to improve the effectiveness of the current response but also to start preparing the health systems for subsequent waves of the current pandemic and future pandemics.